The BCR-ABL(35INS) insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP245...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: O'Hare, Thomas, Zabriskie, Matthew S., Eide, Christopher A., Agarwal, Anupriya, Adrian, Lauren T., You, Huihong, Corbin, Amie S., Yang, Fei, Press, Richard D., Rivera, Victor M., Toplin, Julie, Wong, Stephane, Deininger, Michael W., Druker, Brian J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3217407/
https://ncbi.nlm.nih.gov/pubmed/21908430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-05-349191
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados